Matthew DeCamp is a postdoctoral fellow at the Berman Institute of Bioethics and Division of General Internal Medicine at Johns Hopkins. A practicing internist, his prior PhD research examined the intersection of intellectual property rules, human rights, and access to essential medicines in developing countries. Ongoing research projects include the ethical issues arising from the use of social media in health care, as well as the development and evaluation of an online ethics curriculum for short-term global health training (http://ethicsandglobalhealth.org).
Ruth R. Faden is the Philip Franklin Wagley Professor of Biomedical Ethics and founding Director of the Johns Hopkins Berman Institute. Dr. Faden is the author and editor of many books and articles on biomedical ethics and health policy including Social Justice: The Moral Foundations of Public Health and Health Policy (with Madison Powers), A History and Theory of Informed Consent (with Tom L. Beauchamp), AIDS, Women and the Next Generation (Ruth Faden, Gail Geller and Madison Powers, eds.), and HIV, AIDS and Childbearing: Public Policy, Private Lives (Ruth Faden and Nancy Kass, eds.). Dr. Faden is a member of the Institute of Medicine and a Fellow of the Hastings Center and the American Psychological Association. She has served on numerous national advisory committees and commissions, including President Clinton’s Advisory Committee on Human Radiation Experiments, which she chaired. Dr. Faden is a co-founder of the Hinxton Group, a global community committed to advancing ethical and policy challenges in stem cell science, and the Second Wave project, an effort to ensure that the health interests of pregnant women are fairly represented in biomedical research and drug and device policies. In 2011, Dr. Faden was the recipient of Lifetime Achievement Awards from the American Society for Bioethics and Humanities (ASBH) and Public Responsibility in Medicine and Research (PRIMR). Dr. Faden’s current research focuses on justice theory and on national and global challenges in learning health care systems, health systems design and priority setting, and access to the benefits of global investments in biomedical research. Dr. Faden also works on ethical challenges in biomedical science and in women’s health.
Conrad Fernandez is a professor and head of the division of pediatric hematology/oncology in the Department of Pediatrics, IWK Health Centre. He is cross-appointed in the Departments of Bioethics, Medicine and Postgraduate Studies at Dalhousie University. He is a senior scientist at the Beatrice Hunter Cancer Research Institute. He is chair of the Department of Pediatrics Research Committee. He is a former Chair of the IWK Health Centre Research Ethics Board and the Health Sciences REB at Dalhousie. He is vice-Chair of the Children’s Oncology Group (COG) Bioethics committee and an active member of the COG Renal tumors steering committee. His research interests are in the area of return of research result to participants and pediatric renal tumors.
Steven Joffe is Associate Professor of Pediatrics and of Global Health and Social Medicine at Dana-Farber Cancer Institute, Boston Children’s Hospital, and Harvard Medical School. His work aims to improve our understanding of the nature of clinical research and to apply that improved understanding to the design of research and to interactions with research participants. The major focus of Dr. Joffe’s current work is the ethics of research involving human subjects. He conducts observational and intervention studies of informed consent to clinical trials, as well as children’s participation in decisions about research. He also studies how methodological and ethical considerations intersect in clinical trial design. Dr. Joffe is interested in the implications of human subjects regulations for clinical research and drug development, and in how clinicians and investigators navigate their complex roles. Additional research focuses on ethical issues in genetic and genomic research, such as how researchers should handle genetic information about individual research participants that may be relevant to their current or future health, as well as how whole-genome technologies can be integrated into clinical care. Finally, he studies how the human subjects’ protection system works to protect research participants and what impact that system has on the research process.
Alan Regenberg is the Bioethics Research Manager, a senior staff member at the Johns Hopkins Berman Institute of Bioethics. He leads a team responsible for rapid-response research, broad dissemination and active public engagement around the Institute’s diverse portfolio of scholarship. This includes managing the institute’s internet-based assets and successful, social media-based, public-engagement efforts. Alan also plays a significant role in managing the Berman Institute’s science programs: the Stem Cell Policy and Ethics (SCOPE) Program; the Program in Ethics and Brain Sciences (PEBS-Neuroethics); and the Hinxton Group an international consortium on stem cells, ethics and law. Alan’s research interests are diverse, and have most recently focused on bioethics and social media, global bioethics, stem cell science and neuroethics.
Yoram Unguru is a pediatric hematologist/oncologist and has joint faculty appointments at The Herman and Walter Samuelson Children’s Hospital at Sinai and The Berman Institute of Bioethics, John Hopkins University. Dr. Unguru was a postdoctoral Greenwall Fellow in Bioethics and Public Policy and is board certified both in pediatrics and in pediatric hematology/oncology. Dr. Unguru is deeply interested in surrogate decision-making and the role of children and providers in facilitating shared decision-making among all relevant parties, moral issues that frequently arise in the context of pediatric hematology/oncology. He has published and spoken nationally on this topic, and in 2007, his essay, Pediatric Assent: Should Children Decide and Does it Really Matter? was recognized as the winning bioethics essay by the American Academy of Pediatrics. His interests also include research ethics, end-of-life decision-making, and ethics education. Dr. Unguru served as a consultant to the American Academy of Pediatrics Committee on Pediatric Research tasked with revising the AAP Guidelines for the Ethical Conduct of Studies to Evaluate Drugs in Children. He has also served as a consultant to the American Medical Association Council on Ethical and Judicial Affairs tasked with modernizing pediatric components of the AMA Code of Medical Ethics. As a pediatric resident, he was a founding member of the Pediatric Committee on End-of-Life at The Children’s Hospital at Sinai, which he now chairs. Dr. Unguru continues to serve as an ethics committee and IRB member and is a member of the Children’s Oncology Group, Bioethics Steering Committee as well as a member of the American Society of Clinical Oncology Ethics Committee. Dr. Unguru implemented and directs an ethics curriculum for the pediatric house staff at The Herman and Walter Samuelson Children’s Hospital at Sinai. In 2010, Dr. Unguru was recognized as “Teacher of the Year” by the pediatric house staff at the Children’s Hospital at Sinai.
Peter C. Adamson is Chair of the Children’s Oncology Group (COG), a National Cancer Institute (NCI) supported international consortium of more than 220 childhood centers that conducts clinical-translational research, including large-scale clinical trials, in children with cancer. He is Professor of Pediatrics and Pharmacology at the University of Pennsylvania School of Medicine and Chief of the Division of Clinical Pharmacology and Therapeutics at The Children’s Hospital of Philadelphia. Dr. Adamson is Board Certified in Pediatric Hematology/Oncology and in Clinical Pharmacology. He is an internationally recognized leader in pediatric cancer drug development, having served until 2008 as Chair of the COG’s Developmental Therapeutics Program. Prior to becoming Chair of the COG, Dr. Adamson served as Director for Clinical and Translational Research at The Children’s Hospital of Philadelphia. His laboratory focuses on the clinical pharmacology of new drugs for childhood cancer.
Brooke Bernhardt earned her Doctor of Pharmacy Degree from the University of Georgia. She completed her post-graduate training at the University of Alabama in Birmingham and the University of Virginia. Upon completion of post-graduate training she joined Texas Children’s Hospital and Cancer Center as the Clinical Pharmacy Specialist in Pediatric Hematology and Oncology. Shortly thereafter, she achieved Board Certification in Oncology Pharmacy. She first began working with the Children’s Oncology Group as a pharmacy consultant to the Phase 1 consortium and later assumed the role of Group Pharmacist for the COG. She has been actively involved in a variety of professional organizations including the American Society of Health Systems Pharmacists, the Hematology/Oncology Pharmacy Association, and the Children’s Oncology Group. She serves as a clinical preceptor for the Texas Children’s Hospital Pharmacy Residency programs, the University of Texas College of Pharmacy, and the University of Houston College of Pharmacy.
Lisa Bomgaars is an Associate Professor of Pediatrics at Baylor College of Medicine where she is Associate Vice-Chair of Research for Pediatrics. She is the Director of Clinical Research Operations for the Texas Children’s Cancer and Hematology Centers, Medical Director of the Research Resources Office and Clinical Research Center at Baylor, and Medical Director of QA & Regulatory Affairs for the Children’s Oncology Group. She is a member of the developmental therapeutics & clinical pharmacology New Drug Development Program<http://txch.org/cancer-center/clinical-pharmacology-program/> and the H<http://txch.org/hematology-center/hemophilia-thrombosis-center/young-womens-bleeding-disorder-clinic1/>emostasis and Thrombosis Team. Her research focus relates to the pharmacologic study of new agents. She has experience with pre-clinical and clinical pharmacology research of novel oncologic agents and is a co-investigator on several studies evaluating novel anticoagulation agents for the treatment of thrombosis in pediatrics.
I. Glenn Cohen is an Assistant Professor at Harvard Law School and Co-Director, Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics. He is currently a fellow at the Radcliffe Institute for Advance study and a Greenwall Foundation Faculty Scholar in Bioethics. His research focuses on bioethics and the law and health law, and his current projects focus on reproduction and reproductive technologies, abortion, medical tourism and the globalization of healthcare, comparative professional responsibility, injuries in professional sports, and health policy. He is the editor of “The Globalization of Healthcare: Legal and Ethical Challenges,” which Oxford University Press will release in February 2013, and has the following books currently under contract and in production: “Patients with Passports: Medical Tourism, Ethics and Law” (Oxford University Press), “The Future of Human Subjects Research Regulation” (with Holly Lynch, MIT Press), and “Identified v. Statistical Lives: Ethical, Legal, and Medical Perspectives” (with Norman Daniels and Nir Eyal, Oxford University Press). His work has been published in the leading journals in law (such as the Harvard and Stanford Law Reviews), medicine (such as the New England Journal of Medicine and JAMA), Bioethics (such as the Hastings Center Report and the American Journal of Bioethics), and Public Health (such as the American Journal of Public Health).
Kenneth Cohen is the Director of Pediatric Neuro-Oncology and the Clinical Director in the Division of Pediatric Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He received his undergraduate degree at Brown University, completed medical school at the Upstate Medical University in Syracuse, NY. He did his general Pediatric Residency and Chief Residency at the University of Colorado. He completed his Pediatric Hematology/Oncology Fellowship at Johns Hopkins and has been a member of the faculty since 1994. Dr. Cohen is the co-chair of the High-Grade Glioma committee for the Children’s Oncology Group and in that capacity has a particular research interest in the development of therapeutics for the treatment of high risk brain tumors in children. He is the Chief Medical Officer and head of the Scientific Advisory Board for Solving Kid’s Cancer. He is a Scientific Advisor for the Childhood Brain Tumor Foundation.
Eduvigis Cruz-Arrieta is an Assistant Clinical Professor of Medical Psychology in Psychiatry and Pediatrics at Columbia University College of Physicians & Surgeons (Columbia Uni. Medical Center) has more than10 years of cancer research experience having participated in more than 15 clinical trials (collecting behavioral and neuropsychological data). She has been working as a psychologist since 1988. Dr. Cruz-Arrieta has served as Chair of the Children’s Oncology Group Minority Affairs Committee for 4 years. She has participated on the American Society of Clinical Oncology (ASCO)/COG as Co-Chair of its 2008 Fall Symposium; and also as Lymphoma Research Foundation Advisory Committee member for the ‘Lymphoma Awareness for Multicultural Populations’ grant. Dr. Cruz-Arrieta was a member of Diversity Faculty Committees at New York University Medical Center; Executive Advisory Board Member\ NYUSM & Inst. for Urban & Global Health; and NYU School of Medicine Minority Faculty Committee and School of Medicine Admissions Committee. She actively participated in CureSearch advocacy efforts in Capitol Hill, representing health disparity viewpoints as part of her role as chair of the Minority Affairs Committee. She is currently a member of the Faculty Diversity Task Force at Columbia University P&S, Dept. of Psychiatry. She works as psychologist in the Div. of Pediatric Hematology/Oncology/Bone Marrow Transplantation at Columbia Uni.; also in the Pediatric Psychiatry Clinic of CU Dept. of Psychiatry, providing direct services to children and families from underserved communities in NYC and as a clinical supervisor of doctoral level trainees. As a behavioral scientist, her areas of clinical expertise include: the psychosocial effects of chronic illness; co-morbidity of depression, anxiety, post-traumatic stress with chronic illness; pediatric health-related quality of life and neurocognitive functioning; perception of pain and coping; end of life issues; and diversity and health disparity issues.She is originally from Puerto Rico where she attended the University of Puerto and has resided in New York City for 24 years when she came to pursue doctoral studies at C.U.N.Y. Graduate School & University Center.
Alix Dabb is the Clinical Pharmacy Specialist for Pediatric Oncology in the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. She received her Bachelor of Science in Pharmacy and her Doctor of Pharmacy degree from the Philadelphia College of Pharmacy at the University of the Sciences in Philadelphia. She completed her General Pediatric Pharmacotherapy Residency at the Children’s Regional Hospital at Cooper Hospital University Medical Center in conjunction with the University of the Sciences in Philadelphia. She then completed a Pediatric Oncology Pharmacotherapy Residency at St. Jude Children’s Research Hospital. Alix has been at Johns Hopkins since2003. She additionally serves as a Clinical Associate Professor at the University of Maryland School of Pharmacy. She is an active member of the Children’s Oncology Group pharmacy committee.
Sheri Fink has reported on health, medicine and science in the U.S. and internationally. Her stories have appeared in such publications as the New York Times, Discover and Scientific American and on Public Radio International’s The World. As a staff reporter at the non-profit news organization ProPublica, Fink received a Pulitzer Prize in investigative reporting and a National Magazine Award in reporting for her story “The Deadly Choices at Memorial,” co-published by ProPublica and the New York Times Magazine in 2009. The story, which chronicles decisions made by the medical staff of one New Orleans hospital in the desperate days after Hurricane Katrina, was also recognized with a National Headliner Award, a Sigma Delta Chi Award from the Society of Professional Journalists, and a Dart Award for excellence in coverage of trauma. In 2010, Fink was the lead reporter and co-editor of “Rationing Health,” a radio series on PRI’s The World that examined healthcare rationing around the world. The series received reporting awards from the Overseas Press Club, Association of Health Care Journalists and Global Health Council.
Christine Grady is chief of the Clinical Center’s Department of Bioethics. Her research focuses on research subject recruitment, incentives, vulnerability, and international research ethics. Dr. Grady has written widely in books and scholarly journals on topics in bioethics, HIV disease, and nursing. Dr. Grady received a bachelor’s degree in nursing and biology from Georgetown University, a master’s degree in community health nursing from Boston College, and a doctoral degree in philosophy and bioethics from Georgetown University. She is currently a member of President Obama’s Commission for the Study of Bioethical Issues. She is a senior research fellow at the Kennedy Institute of Ethics and was elected as a fellow of both the American Academy of Nursing and the Hastings Center. She is a member of an institutional review board for the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Arthritis and Musculoskeletal and Skin Diseases. She has participated in numerous intergovernmental task forces and is the recipient of several awards, including the NIH Clinical Center Director’s Award in 2009, NIH Director’s Award in 2007 and 1999 and the Assistant Secretary of Health Award in 1988. She serves on three editorial boards of professional journals in bioethics and nursing; she has lectured widely at national and international conferences, professional societies, universities, and healthcare institutions on ethical issues in clinical research and clinical care. She was formerly assistant director for clinical science at the National Institute of Nursing Research.
Howard Gwon has been very active in emergency management since July 1, 1988 as the Administrator of the Emergency Medicine Department from 1986 to 1990. Mr. Gwon continued to Chair the Hospital’s Emergency Management (Preparedness) Committee and the Hospital’s Disaster Control Administrator (from 7/1/88 to 7/31/2006) while serving as the Administrator for the Department of Psychiatry. This expertise has spanned two decades and he has served four different senior administration groups to develop a comprehensive emergency management program. On August 1, 2006, the Hospital and the School of Medicine established the Office of Emergency Management and named him as its first full time Administrator. This responsibility provides consistent communication and standardized processes to organizational leaders, department leadership, approximately 250 departmental disaster coordinators and external liaisons (State, city, community) to plan, prepare and respond to the various types of disasters that may impact our community, Hopkins’ facilities and the region. On January 6, 2011 he was promoted to a Senior Director to oversee preparedness for the rest of the Health System organizations. Finally, he holds an adjunct faculty position, as Senior Associate, in the Department of Environmental Sciences in the Johns Hopkins Bloomberg School of Public Health.
Mekdese Kassa, Operations and Clinical Manager at Sinai Hospital of Baltimore .
Jennifer Kesselheim attended college at the University of Wisconsin and then completed her MD degree at the University of Pennsylvania. While at Penn, she earned a Masters degree in medical ethics. During her residency training in pediatrics at Boston Children’s Hospital, Dr. Kesselheim developed and implemented an ethics curriculum for residents and engaged in research about how pediatricians learn ethics during their training. As a fellow in pediatric hematology-oncology, Dr. Kesselheim completed coursework to earn a Masters degree in education from Harvard. As an educator, she serves as an associate fellowship program director and, on a national level, she designs curricula and evaluation instruments for trainees related to humanism, ethics, and professionalism. As an investigator, her research continues to focus on the methods and outcomes of physician education in the areas of ethics and professionalism. She chairs the Certification and Continuing Education Committee for the American Society of Pediatric Hematology-Oncology and is a member of the Cancer Education Committee (Bioethics track) for the American Society of Clinical Oncology. She co-chairs the Ethics Advisory Committee at Dana-Farber Cancer Institute where she also serves on a task force dedicated to the Institute’s response to drug shortages. Dr. Kesselheim lives in Jamaica Plain, MA with her husband, 5 year old son (Max) and infant daughter (Sydney).
Eric Kodish is the Director of Cleveland Clinic’s Center for Ethics, Humanities, and Spiritual Care. He also serves as the F. J. O’Neill Professor and Chairman of the Department of Bioethics, Executive Director of the Cleveland Fellowship in Advanced Bioethics, and Professor of Pediatrics at the Lerner College of Medicine of Case Western Reserve University. From 1993-2004, he cared for children with cancer and blood diseases at Rainbow Babies and Children’s Hospital, where he was the founding director of the Rainbow Center for Pediatric Ethics. His areas of expertise include childhood cancer and blood diseases, pediatric ethics, end-of-life issues, and research ethics. He received the Distinguished Alumni Award from the Northeast Ohio Medical University in 2001, and was elected Chair of its Board of Trustees in 2011. Dr. Kodish has been Principal Investigator on a series of three NCI funded multi-site studies of informed consent in childhood cancer. The American Cancer Society, Greenwall Foundation, Cleveland Foundation and the Cancer Treatment Research Foundation have also funded his work. He has been an active committee member and consultant at the Institute of Medicine. He served as Chair of the Bioethics Committee of the Children’s Oncology Group from 2002-2008, and was an appointed member of the Committee on Bioethics of the American Academy of Pediatrics from 1999-2005. He has also served on the Science and Medicine Advisory Committee of the United States Holocaust Memorial Museum and on the Recombinant DNA Advisory Committee (RAC) at the NIH. He is currently a member of the Advisory Council at the National Center for Advancing Translational Sciences (NCATS) at NIH. Previously, he has been a member of the HHS Secretary’s Advisory Committee on Human Research Protections Subcommittee for Research Involving Children at the Office of Human Research Protections and the NCI’s Pediatric Central IRB. He is the author of numerous peer-reviewed publications in journals including JAMA and the New England Journal of Medicine, as well as book chapters and reviews. He is the editor of “Ethics and Research with Children: A Case-Based Approach,” published by Oxford University Press (February 2005).
Revonda B Mosher is a pediatric nurse practitioner who recently retired from The Herman and Walter Samuelson Children’s Hospital at Sinai. She has worked in pediatric oncology as a staff nurse and then as a pediatric nurse practitioner for 40+ years. Ms Mosher received a diploma of nursing from Cabarrus Memorial Hospital School of Nursing, Concord, NC; a BSN from George Mason University, Fairfax, VA and a MSN/PNP from the University of Virginia, Charlottesville, VA. Ms Mosher is active in the Association of Pediatric Hematology Oncology Nurses on the local and national level. Also Ms Mosher has been involved in the Children’s Oncology Group for many years as a member of several committees, including the Nursing Steering Committee and the nursing representative on the Rare Tumors Committee. Ms Mosher was the coordinator of the Survivors clinics at Children’s National Medical Center and also at the Samuelson Children’s Hospital at Sinai during her tenure at each institution. Approximately 25 articles have been published by Ms. Mosher.
Robert “Skip” Nelson is currently the Deputy Director and Senior Pediatric Ethicist in the Office of Pediatric Therapeutics, Office of the Commissioner at the U.S. Food and Drug Administration. After receiving his M.D. degree from Yale University, Dr. Nelson trained in pediatrics (Massachusetts General Hospital), neonatology and pediatric critical care (University of California, San Francisco). He has a Master of Divinity degree from Yale Divinity School and a Ph.D. in The Study of Religion from Harvard University. Immediately prior to joining FDA full-time in 2009, he was Professor of Anesthesiology, Critical Care and Pediatrics at The Children’s Hospital of Philadelphia and University of Pennsylvania School of Medicine. Dr. Nelson was a member (2004-2006) and former Chair (2005-2006) of the FDA Pediatric Advisory Committee and the Pediatric Ethics Subcommittee. He was a member of the Subcommittee on Research Involving Children of the Secretary’s Advisory Committee on Human Research Protections (2003-2006), and the Human Studies Review Board of the Environmental Protection Agency (2006). Dr. Nelson was a member of the Committee on Clinical Research Involving Children of the Institute of Medicine (2002-2004), and a member and former Chair of the Committee on Bioethics of the American Academy of Pediatrics (1994-2001). Dr. Nelson is the Editor-in-Chief of the American Journal of Bioethics (AJOB) – Primary Research, which publishes empirical research in bioethics. Dr. Nelson’s academic research explored various aspects of child assent and parental permission, including risk perception and voluntary choice, and was funded by the Greenwall Foundation, the National Institutes of Health, and the National Science Foundation.
Rebecca Pentz is Professor of Hematology and Oncology in Research Ethics at Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia. She does empirical ethics research on such issues as informed consent, phase 1 research (first use of a drug in humans) and stresses on siblings of children with cancer, as well as helping researchers with their protocols to make them ethically sound. In 2000, she moved to Atlanta from Houston where she was the Clinical Ethicist at The University MD Anderson Cancer Center. As Clinical Ethicist she worked closely with the Administration on policy development including a white paper on rationing. Becky has several national commitments. She is on the St. Jude and the Children’s Oncology Group’s ethics committees. She sits on one of the Centers for Disease Control institutional review boards. She advises multiple national committees including the HHS Secretary’s committee on cord blood banking. At Emory, she is chair of the Dean’s Faculty Advisory Committee, member of the Winship scientific review committee and ACTSI’s safety and ethics committees.
Nicholson Price is an Academic Fellow at the Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics at Harvard Law School. After receiving his A.B. from Harvard College, he earned a J.D. and a Ph.D. in Biological Sciences from Columbia University, where his doctoral work focused on methods development for protein crystallography and medium-throughput screening for enzymatic inhibitors. After law school, he clerked for Judge Carlos T. Bea of the U.S. Court of Appeals for the Ninth Circuit, and was a Visiting Consortium Scholar at the UCSF/UC Hastings Consortium on Law, Science and Health Policy. Nicholson’s past scholarship has involved genetic testing patents and the implications of human cloning for family law. His current scholarship has two broad foci. First, he is studying the role of innovation policy in pharmaceutical manufacturing. Second, he is working on a variety of issues related to genetic testing and genetic sequencing, including the role of gene patents and the return of individual results in genetic research.
Gregory H. Reaman was the first Group C hair of the Children’s Oncology Group (COG). The COG was formed in March, 2000, by the merger of four legacy pediatric cancer research organizations and is comprised of over 230 member institutions, responsible for the treatment of 90 percent of children with cancer in North America. Dr. Reaman is a professor of pediatrics and medicine at the George Washington University School of Medicine and Health Sciences and a member of the division of Hematology-Oncology at Children’s National Medical Center in Washington, DC, which he directed for 17 years. Dr. Reaman is a graduate of Loyola University Chicago-Stritch School of Medicine, and completed his pediatrics training at McGill University/the Montreal Children’s Hospital. His post graduate training in oncology was obtained at the Pediatric Oncology Branch of the National Cancer Institute where he served as an Investigator prior to coming to Children’s Hospital, and where he continues as a member of the staff . Dr. Reaman serves or has served on the editorial boards of Leukemia, Journal of Clinical Oncology, Journal of Pediatric Hematology/Oncology, Pediatric Blood and Cancer, The Oncologist, Cancer, and Physicians Data Query (PDQ), National Cancer Institute as well as http://www.PLWC.org (People Living with Cancer). He has served as an associate editor of Cancer and associate editor of Leukemia and Lymphoma. He was the executive vice-president for Medical and Scientific Affairs for the National Childhood Cancer Foundation (NCCF) and a member of its Board of Trustees. Previously, he served on the Board of Directors of the American Cancer Society and chaired its Task Force on Children and Cancer. In addition, Dr. Reaman served on the Board of Directors of the American Society of Clinical Oncology (ASCO) and chaired its Patient Education Committee, Educational Program Committee, and ASCO Membership Committee. He is a member of the Alliance for Childhood Cancer, a member of the Data Safety Monitoring Board of the National Cancer Institute’s Clinical Oncology Program, and was a member of the Food and Drug Administration’s Oncologic Drugs Advisory Committee and chaired its Pediatric Subcommittee. He has served on numerous NCI committees and has chaired the Clinical Oncology Study Section. He is the author of more than 300 peer-reviewed manuscripts.
A. Kim Ritchey recently stepped down as Chief of Pediatric Hematology/Oncology at Children’s Hospital of Pittsburgh of UPMC and is currently Vice Chair for Clinical Affairs for the Department of Pediatrics and Professor of Pediatrics at the University of Pittsburgh School of Medicine. He completed medical school at the University of Cincinnati School of Medicine and then was a pediatric resident at Johns Hopkins Hospital. He was a fellow in Pediatric Hematology/Oncology at Yale University and stayed on the faculty for a number of years before moving to Morgantown, WV as Chief of the Division of Pediatric Hematology/Oncology at West Virginia University. He moved to the position of Chief of Pediatric Hematology/Oncology in Pittsburgh in 1998. His primary research interest has been in clinical oncology and specifically isolated central nervous system relapse of leukemia. He is the PI for Children’s Oncology Group research at Children’s Hospital of Pittsburgh of UPMC. He is the President of the American Society of Pediatric Hematology/Oncology. He is on the Board of Directors of the American Board of Pediatrics and also serves on the ABP Executive Committee.
Philip Rosoff Clinical Interests: Clinical medical ethics, pediatric oncology. long-term follow-up of childhood cancer survivors Research Interests: My main interests are applied clinical ethics with a concentration in medical decision-making including equitable allocation of scarce resources (rationing). In this area, I have done work on planning for pandemic influenza and allocation of drugs during shortages. I play a major role in the Clinical Ethics Service at Duke Hospital and chair the hospital’s Ethics Committee.
Carol Taylor is a senior research scholar in the Kennedy Institute of Ethics at Georgetown University and a Professor of Nursing. At Georgetown Carol directs an innovative ethics curriculum grounded in a rich notion of moral agency for advanced practice nurses. She teaches in the undergraduate nursing curriculum, directs a practicum in clinical ethics for graduate students in the philosophy program, serves on the ethics committee, conducts ethics rounds and ethics case presentations, and develops professional seminars in clinical ethics for health care professionals and the public. Her research interests include clinical and professional ethics, and organizational integrity. Carol has a PhD in Philosophy with a concentration in bioethics from Georgetown University and a Master’s Degree in Medical-Surgical Nursing from Catholic University; She now works closely with health care professionals and leaders who are exploring the ethical dimensions of their practice. She lectures internationally and writes on various issues in healthcare ethics and serves as an ethics consultant to systems and professional organizations.
Joseph M. Wiley, is Division Chief of Pediatric Hematology-Oncology and Chairman of the Department of Pediatrics at the Herman and Walter Samuelson Children’s Hospital at Sinai Hospital He has been active in clinical research in pediatric hematology-oncology with ~ 50 publications and an equal number of abstracts. He has served as an IRB Chairman, ad hoc editor for many Pediatric Oncology and Infectious Disease journals, and was Director of Pediatric Bone Marrow Transplant for 7 years at Chapel Hill, NC. He is best known for his work in supportive care and infections in cancer patients, particularly fungal infections. He is a member of the Cancer and Control Committee for COG as well as the NHL Committee. He currently co-Chairs a national, COG protocol for fungal infection prevention in AML patients. He has chaired numerous Advisory committees nationally and internationally on fungal infections in cancer patients.
Catherine L. Woodman is an Associate Professor in the departments of Psychiatry and Family Medicine at the University of Iowa. She has been an Institutional Review Board member at the University of Iowa for 21 years and an IRB chair for 7 years. She was a member of the NCI pediatric CIRB for five years. Her expertise is in ethics and research in children. Dr. Woodman has been a member of COG for 10 years and has been a member of the patient advocacy committee, the ethics committee, and the CNS tumors committee. She is also a member of the Phase I/Phase II DSMC. Dr. Woodman is the parent of a 12 year survivor of medulloblastoma.
Nathan Risinger is a Research Assistant at the Johns Hopkins Berman Institute of Bioethics. He graduated with honors from Johns Hopkins University and contributes to The Huffington Post and Bioethics Bulletin.